Therapeutics

The emergence of antibiotic resistance has severely reduced the effectiveness of all antibiotics clinically used today. At the same time very few fundamentally new antibiotics have been developed in the past 20 years. Thus, we are rapidly running out of treatment options for CPE infections. Development of new lead compounds is a difficult, high-risk problem that requires a multidisciplinary approach.

CARe aim to, in collaboration with health care and industry, identify new treatment options and to develop new antibiotic substances.

Research projects

Development of metallo-beta-lactamase inhibitors
Development of long lasting antibiotics
Detection and Characterization of Genes Associated with the Synthesis of Bioactive Compounds in Bacteria from Marine Sediments of the Chilean Coast: Searching for Novel Antimicrobial Agents
Mode of action of violacein in pathogenic Gram negative bacteria and its development as an antibacterial agent
Mechanism of action of Carbapenemases, and development of inhibitors against these
Development of inhibitors targeting Leukotoxins
Exotoxin A Pseudomonas aeruginosa; mechanism and inhibition
Biomedical photonics applied towards noninvasive imaging of bacterial biofilms
Virulence inhibitors for the treatment of soft tissue infections
Studies to elucidate the binding capacities of Enterotoxigenic Escherichia coli (ETEC) colonisation factor fimbriae to human glycans
Inhibition of Bacterial Sialic acid Transporters
Mode of action of natural products in pathogenic Gram negative bacteria and their development as antibacterial agents
Genome-based natural product discovery: Characterization of bioactive compounds in marine Actinobacteria

Last modified

17 January 2022